HAE vs TFX vs HOLX

For growth investors, Hologic, Inc.

(HOLX) is the stronger pick with 1. 7% revenue growth year-over-year, versus -34. 6% for Teleflex Incorporated (TFX). Haemonetics Corporation (HAE) offers the better valuation at 26. 5x trailing P/E (11. 0x forward), making it the more compelling value choice. Analysts rate Haemonetics Corporation (HAE) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Haemonetics Corporation (HAE) is the cheapest at 26.

5x versus Hologic, Inc. at 30. 5x. On forward P/E, Haemonetics Corporation is actually cheaper at 11. 0x.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -66. 4% for Teleflex Incorporated (TFX). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus TFX's -10. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus Teleflex Incorporated's 1. 06β — meaning TFX is approximately 158% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 137% for Haemonetics Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hologic, Inc.

(HOLX) is pulling ahead at 1. 7% versus -34. 6% for Teleflex Incorporated (TFX). On earnings-per-share growth, the picture is similar: Hologic, Inc. grew EPS -25. 0% year-over-year, compared to -1468. 2% for Teleflex Incorporated. Over a 3-year CAGR, HAE leads at 4. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -45. 4% for Teleflex Incorporated — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus 11. 7% for HAE. At the gross margin level — before operating expenses — HOLX leads at 61. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Haemonetics Corporation (HAE) trades at 11.

0x forward P/E versus 19. 6x for Teleflex Incorporated — 8. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HAE: 55. 6% to $84. 60.

In this comparison, TFX (1.

0% yield) pays a dividend. HAE, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Both have compounded well over 10 years (HOLX: +124. 3%, TFX: -10. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

TFX pays a dividend while HAE, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.